好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Blood pressure changes during Alemtuzumab infusion for persons with MS
Multiple Sclerosis
P7 - Poster Session 7 (5:30 PM-6:30 PM)
9-003
To study blood pressure (BP) changes during alemtuzumab infusions in persons with multiple sclerosis (PwMS).

Alemtuzumab is an anti- CD52 therapy given intravenously for 5 and 3 days, 12 months apart, with re-treatment as necessary. Intracerebral haemorrhage had been documented during or following administration of alemtuzumab, with a potential relationship to BP changes.
Retrospective review of systolic (S) and Diastolic (D) BP in PwMS receiving alemtuzumab at the London (Ontario) MS Clinic.
Thirty-one patients were identified; 64.5% (22) were female. Mean age and disease duration were 35.2 ±7.1 and 9.2 ± 5.4 years. There was no history of hypertension or vascular events. Seven (22%) PwMS completed one cycle (5 doses), while 2 (6.5%) received 3 cycles (11 doses). Mean baseline SBP was 119.8±15.1mmHg, 118.8±14.3mmHg, and 106.5±6.1mmHg, while mean DBP was 75.3 ± 9.2mmHg, 74.1 ± 12.4 mmHg, and 69.2±4.3 mmHg in dose one, six, and nine respectively. During cycle one, SBP increased by 19.2 ±9.4 mmHg, with comparable percentage increases over the 5 infusions (16%, 22%, 17%, 11%, 13%) respectively. DBP increased by 6.2 ±3.8mmHg with similar percent increases over the 5 infusions (8.4%, 11.5%, 5.5%, 7%, 3%). For the 2nd cycle, SBP increased by 16.9 ± 3.2mmhg, with similar increases over the 3 days (12%, 15%, 17%). DBP increased by 5.4 ± 4.2mmhg (11%, 9%, 12.8%). Third cycle demonstrated similar results: SBP and DBP increased by 8.9 ± 2.3 mmHg, 4.2 ± 1.9mmHg respectively, with increasing percent for SBP and DBP, 10%, 70%, 11.8% and 3%, 2%, 6.5% respectively. Overall, seventeen (54.8%) patients had increasing BP by ≥ 20% from baseline and 9 (29%) had increased by ≥ 20 mmHg from baseline.
This is the first study documenting BP changes during alemtuzumab infusions in PwMS, demonstrating significant increases in BP during all infusions.
Authors/Disclosures
Eslam H. Shosha, MD (KKH-College of Medicine-Majmaah University)
PRESENTER 		Dr. Shosha has nothing to disclose.
Courtney S. Casserly, MD, FAAN (London Health Sciences Center) Dr. Casserly has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Casserly has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Soliris. Dr. Casserly has received personal compensation in the range of $500-$4,999 for serving as a Consultant for biogen idec. Dr. Casserly has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for sanofi genzyme. Dr. Casserly has received personal compensation in the range of $500-$4,999 for serving as a Consultant for roche. Dr. Casserly has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Casserly has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Horizon Theraputics. Dr. Casserly has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for roche. Dr. Casserly has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Soliris. Dr. Casserly has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for novartis. Dr. Casserly has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen Idec. Dr. Casserly has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMG Serono. The institution of Dr. Casserly has received research support from Biogen Idec. The institution of Dr. Casserly has received research support from Western Libraries. The institution of Dr. Casserly has received research support from Western University.
Christine Tomkinson, MD No disclosure on file
Sarah A. Morrow, MD, MSC, FRCPC, FAAN Dr. Morrow has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono/Merck. Dr. Morrow has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Celgene. Dr. Morrow has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Morrow has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Morrow has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SanofiGenzyme. Dr. Morrow has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen Idec. Dr. Morrow has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Novartis. Dr. Morrow has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Roche. The institution of Dr. Morrow has received research support from Celgene. The institution of Dr. Morrow has received research support from SanofiGenzyme. The institution of Dr. Morrow has received research support from Novartis.